Drugs / PIK-HER2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02632201 | Sep 2015 → Mar 2017 | gastric cancer | Second Military Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIK-HER2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02632201 ↗ |
| Modality | Cell therapy | “This study designs a novel therapy using PIK-HER2 cells.” NCT02632201 ↗ |
| Route | Intravenous | “PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion” NCT02632201 ↗ |